{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:06:12Z","timestamp":1786637172497,"version":"build-2736575974"},"reference-count":76,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov? Agentura Cesk? Republiky","doi-asserted-by":"publisher","award":["GA CR 22-07138O"],"award-info":[{"award-number":["GA CR 22-07138O"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005370","name":"Gates Cambridge Trust","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Apollo Therapeutics Ltd","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CK2 is a constitutively active serine\/threonine kinase implicated in cancer, viral infection, and neurodegeneration, but its conserved ATP-binding site and complex holoenzyme assembly have long made selective inhibition challenging. This Perspective discusses three complementary strategies for selective CK2 inhibition: targeting the CK2\u03b1\/\u03b2 interface with small molecules, disrupting the same interface with conformationally constrained peptides, and exploiting the cryptic \u03b1D pocket for dual-site inhibitor design. CK2\u03b1\/\u03b2-interface inhibitors, including CAM187, CAM7117 and P8C9, established structurally validated routes to modulate holoenzyme assembly and \u03b2-dependent substrate phosphorylation. Validation of the \u03b1D pocket as a ligandable cryptosteric site enabled dual-site ligands such as CAM4066 and \u03b1D-directed inhibitors such as CAM4712, followed by related advances including AB668, KDX1381 and Biv5. These efforts culminated in APL-5125, a highly selective, subnanomolar dual-site inhibitor now in Phase 1\/2 clinical evaluation.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c00643","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:12:18Z","timestamp":1785849138000},"page":"17584-17601","source":"Crossref","is-referenced-by-count":0,"title":["Selective Inhibition\nof CK2: Emerging Strategies and\nFuture Directions"],"prefix":"10.1021","volume":"69","author":[{"given":"Aryaman R.","family":"Sokhal","sequence":"first","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1EW"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Krajcovicova","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1EW"]},{"name":"Palacky University , , ,","place":["Olomouc, Czech Republic, 77900"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Iegre","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1EW"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-0474","authenticated-orcid":true,"given":"Paul","family":"Brear","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1GA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-4976","authenticated-orcid":true,"given":"Claudia","family":"De Fusco","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1EW"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-5648","authenticated-orcid":true,"given":"Paul A.","family":"Glossop","sequence":"additional","affiliation":[{"name":"Sandexis Medicinal Chemistry Ltd , Discovery Park , ,","place":["Sandwich, United Kingdom, CT13 9FF"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Cawkill","sequence":"additional","affiliation":[{"name":"Apollo Therapeutics Ltd , ,","place":["Cambridge, United Kingdom, CB1 2JH"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-4070","authenticated-orcid":true,"given":"Marko","family":"Hyvo\u0308nen","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1GA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7355-2824","authenticated-orcid":true,"given":"David R.","family":"Spring","sequence":"additional","affiliation":[{"name":"University of Cambridge , , ,","place":["Cambridge, United Kingdom, CB2 1EW"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"5","key":"2026081311084993000_cit1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"2026081311084993000_cit2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00441-010-1068-3","article-title":"Cellular Regulators\nof Protein Kinase CK2","volume":"342","author":"Montenarh","year":"2010","journal-title":"Cell Tissue Res."},{"issue":"8","key":"2026081311084993000_cit3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1110\/ps.04637904","article-title":"Evolutionary Constraints\nAssociated with Functional\nSpecificity of the CMGC Protein Kinases MAPK, CDK, GSK, SRPK, DYRK,\nand CK2\u03b1","volume":"13","author":"Kannan","year":"2004","journal-title":"Protein Sci."},{"key":"2026081311084993000_cit4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbrep.2015.08.011","article-title":"Predicting\nCK2 Beta-Dependent Substrates Using Linear Patterns","volume":"4","author":"Nu\u0301n\u0303ez de Villavicencio-Di\u0301az","year":"2015","journal-title":"Biochem. Biophys. Rep."},{"issue":"1","key":"2026081311084993000_cit5","doi-asserted-by":"publisher","first-page":"14689","DOI":"10.1038\/s41598-020-71854-6","article-title":"Preclinical Efficacy\nof CIGB-300, an Anti-CK2 Peptide, on Breast Cancer Metastasic Colonization","volume":"10","author":"Gottardo","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"2026081311084993000_cit6","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1021\/acs.jmedchem.2c01523","article-title":"Strategies of Targeting\nCK2 in Drug Discovery: Challenges, Opportunities,\nand Emerging Prospects","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"25","key":"2026081311084993000_cit7","doi-asserted-by":"publisher","first-page":"22509","DOI":"10.1074\/jbc.M200486200","article-title":"Unique Activation Mechanism of Protein\nKinase CK2: the N-Terminal Segment is Essential for Constitutive Activity\nof the Catalytic Subunit but not of the Holoenzyme","volume":"277","author":"Sarno","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"2026081311084993000_cit8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3892\/ijo.28.3.685","article-title":"Protein Kinase\nCK2 Subunits Are Positive Regulators of AKT Kinase","volume":"28","author":"Guerra","year":"2006","journal-title":"Int. J. Oncol."},{"issue":"27","key":"2026081311084993000_cit9","doi-asserted-by":"publisher","first-page":"18394","DOI":"10.1074\/jbc.M601112200","article-title":"Casein Kinase 2 Is Activated and Essential for Wnt\/\u03b2-Catenin\nSignaling","volume":"281","author":"Gao","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026081311084993000_cit10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","article-title":"A CK2-Dependent\nMechanism for Activation\nof the JAK-STAT Signaling Pathway","volume":"118","author":"Zheng","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026081311084993000_cit11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The Tumor Suppressor\nPTEN Is Phosphorylated by the\nProtein Kinase CK2 at Its C Terminus: implications for PTEN Stability\nto Proteasome-Mediated Degradation","volume":"276","author":"Torres","year":"2001","journal-title":"J. Biol.\nChem."},{"issue":"3","key":"2026081311084993000_cit12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bbapap.2009.07.018","article-title":"Addiction to Protein\nKinase CK2: A Common Denominator\nof Diverse Cancer Cells?","volume":"1804","author":"Ruzzene","year":"2010","journal-title":"Biochim. Biophys.\nActa BBA - Proteins Proteomics"},{"issue":"10","key":"2026081311084993000_cit13","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/biomedicines9101361","article-title":"CK2 Regulation: Perspectives in 2021","volume":"9","author":"Roffey","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"2026081311084993000_cit14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/kinasesphosphatases1020009","article-title":"Protein Kinase CK2 and SARS-CoV-2:\nAn Expected Interplay Story","volume":"1","author":"Quezada Meza","year":"2023","journal-title":"Kinases Phosphatases"},{"issue":"19","key":"2026081311084993000_cit15","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1093\/emboj\/20.19.5320","article-title":"Crystal Structure of\nHuman Protein Kinase CK2: Insights into Basic Properties of the CK2\nHoloenzyme","volume":"20","author":"Niefind","year":"2001","journal-title":"EMBO J."},{"key":"2026081311084993000_cit16","doi-asserted-by":"publisher","first-page":"1393485","DOI":"10.3389\/fimmu.2024.1393485","article-title":"Protein Kinase CK2\u03b1\nIs Overexpressed in Classical Hodgkin Lymphoma, Regulates Key Signaling\nPathways, PD-L1 and May Represent a New Target for Therapy","volume":"15","author":"Ruggeri","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"2026081311084993000_cit17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein Kinase Biochemistry\nand Drug Discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorganic Chem."},{"issue":"2","key":"2026081311084993000_cit18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/kinasesphosphatases2020007","article-title":"CK2 Inhibitors Targeting Inside and\nOutside the Catalytic\nBox","volume":"2","author":"Day-Riley","year":"2024","journal-title":"Kinases Phosphatases"},{"issue":"11","key":"2026081311084993000_cit19","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1039\/C6SC02335E","article-title":"Specific Inhibition\nof CK2\u03b1 from an Anchor Outside the Active Site","volume":"7","author":"Brear","year":"2016","journal-title":"Chem. Sci."},{"issue":"13","key":"2026081311084993000_cit20","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1016\/j.bmc.2017.04.037","article-title":"A Fragment-Based\nApproach Leading to the Discovery of a Novel Binding Site and the\nSelective CK2 Inhibitor CAM4066","volume":"25","author":"De Fusco","year":"2017","journal-title":"Bioorg. Med.\nChem."},{"issue":"20","key":"2026081311084993000_cit21","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1039\/D1OB00257K","article-title":"Chemical Probes Targeting the Kinase CK2: A Journey\nOutside the Catalytic Box","volume":"19","author":"Iegre","year":"2021","journal-title":"Org. Biomol. Chem."},{"issue":"2","key":"2026081311084993000_cit22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/(sici)1522-2683(19990201)20:2&lt;391::aid-elps391&gt;3.0.co;2-n","article-title":"Protein Kinase CK2\nand Its Role in Cellular Proliferation,\nDevelopment and Pathology","volume":"20","author":"Guerra","year":"1999","journal-title":"Electrophoresis"},{"issue":"2","key":"2026081311084993000_cit23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.chembiol.2007.12.012","article-title":"The CK2\u03b1\/CK2\u03b2\nInterface of Human Protein Kinase CK2 Harbors a Binding Pocket for\nSmall Molecules","volume":"15","author":"Raaf","year":"2008","journal-title":"Chem. Biol."},{"issue":"1","key":"2026081311084993000_cit24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-008-9821-6","article-title":"Identification\nof Chemical Inhibitors\nof Protein-Kinase CK2 Subunit Interaction","volume":"316","author":"Laudet","year":"2008","journal-title":"Mol.\nCell. Biochem."},{"issue":"12","key":"2026081311084993000_cit25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.18632\/oncotarget.361","article-title":"Antitumoral Activity\nof Allosteric Inhibitors of Protein Kinase CK2","volume":"2","author":"Moucadel","year":"2011","journal-title":"Oncotarget"},{"issue":"19","key":"2026081311084993000_cit26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9","article-title":"Rule of Three\u2019\nfor Fragment-Based Lead Discovery?","volume":"8","author":"Congreve","year":"2003","journal-title":"Drug Discovery\nToday"},{"issue":"1","key":"2026081311084993000_cit27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and\nComputational Approaches to Estimate Solubility and Permeability in\nDrug Discovery and Development Settings1","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv.\nDrug Delivery Rev."},{"issue":"11","key":"2026081311084993000_cit28","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.bmc.2018.05.011","article-title":"Novel Non-ATP Competitive Small Molecules\nTargeting the CK2 \u03b1\/\u03b2 Interface","volume":"26","author":"Brear","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"2026081311084993000_cit29","doi-asserted-by":"publisher","DOI":"10.17863\/CAM.189","article-title":"Research Data Supporting\nAchieving Small\u2013Molecule Disruption of the CK2\u03b1\/CK2\u03b2\nProtein\u2013Protein Interaction within the Protein Kinase CK2 Heterotetramer","author":"Seetoh","year":"2016","journal-title":"pubMed central"},{"issue":"1","key":"2026081311084993000_cit30","doi-asserted-by":"publisher","first-page":"15893","DOI":"10.1038\/s41598-019-52141-5","article-title":"Discovery of Holoenzyme-Disrupting\nChemicals as Substrate-Selective CK2 Inhibitors","volume":"9","author":"Kufareva","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"2026081311084993000_cit31","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1021\/acschembio.0c00486","article-title":"Gini Coefficients\nas a Single Value Metric to Define\nChemical Probe Selectivity","volume":"15","author":"Ursu","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"19","key":"2026081311084993000_cit32","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1093\/emboj\/20.19.5320","article-title":"Crystal Structure\nof Human Protein Kinase CK2: Insights into Basic Properties of the\nCK2 Holoenzyme","volume":"20","author":"Niefind","year":"2001","journal-title":"EMBO J."},{"issue":"3","key":"2026081311084993000_cit33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1042\/BJ20070825","article-title":"Structure-Based Design\nof Small Peptide\nInhibitors of Protein Kinase CK2 Subunit Interaction","volume":"408","author":"Laudet","year":"2007","journal-title":"Biochem. J."},{"issue":"1","key":"2026081311084993000_cit34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ph10010016","article-title":"Search of Small Molecule Inhibitors\nTargeting the Flexible CK2 Subunit Interface","volume":"10","author":"Bestgen","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"4","key":"2026081311084993000_cit35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nprot.2015.033","article-title":"A Two-Component\n\u201cdouble-Click\u201d Approach to Peptide Stapling","volume":"10","author":"Lau","year":"2015","journal-title":"Nat. Protoc."},{"issue":"6","key":"2026081311084993000_cit36","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1021\/jacs.6b10234","article-title":"Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition\nDomain of Tankyrase","volume":"139","author":"Xu","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"20","key":"2026081311084993000_cit37","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1039\/C8SC00284C","article-title":"Stapled Peptides\nas a New Technology\nto Investigate Protein\u2013Protein Interactions in Human Platelets","volume":"9","author":"Iegre","year":"2018","journal-title":"Chem. Sci."},{"issue":"7","key":"2026081311084993000_cit38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1021\/acs.bioconjchem.6b00209","article-title":"A Helix-Stabilizing Linker Improves\nSubcutaneous Bioavailability of a Helical Peptide Independent of Linker\nLipophilicity","volume":"27","author":"Zhang","year":"2016","journal-title":"Bioconjugate Chem."},{"issue":"19","key":"2026081311084993000_cit39","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1039\/C9SC00798A","article-title":"Efficient Development of Stable and\nHighly Functionalised Peptides Targeting the CK2\u03b1\/CK2\u03b2\nProtein\u2013Protein Interaction","volume":"10","author":"Iegre","year":"2019","journal-title":"Chem. Sci."},{"issue":"5","key":"2026081311084993000_cit40","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1039\/C4SC00045E","article-title":"Functionalised Staple\nLinkages for Modulating the Cellular Activity of Stapled Peptides","volume":"5","author":"Lau","year":"2014","journal-title":"Chem. Sci."},{"issue":"30","key":"2026081311084993000_cit41","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1039\/D2CC00707J","article-title":"Development of Small Cyclic Peptides\nTargeting the CK2\u03b1\/\u03b2 Interface","volume":"58","author":"Atkinson","year":"2022","journal-title":"Chem. Commun."},{"issue":"43","key":"2026081311084993000_cit42","doi-asserted-by":"publisher","first-page":"8645","DOI":"10.1039\/c2ob26022k","article-title":"A Subnanomolar\nFluorescent Probe for Protein Kinase CK2 Interaction Studies","volume":"10","author":"Enkvist","year":"2012","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"2026081311084993000_cit43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1006\/bbrc.1995.1354","article-title":"Halogenated Benzimidazoles\nand Benzotriazoles as Selective Inhibitors of Protein Kinases CK-I\nand CK-II from Saccharomyces Cerevisiae and Other\nSources","volume":"208","author":"Szyszka","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"2026081311084993000_cit44","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.bbapap.2013.01.018","article-title":"Exploiting\nthe Repertoire of CK2 Inhibitors to Target\nDYRK and PIM Kinases","volume":"1834","author":"Cozza","year":"2013","journal-title":"Biochim. Biophys. Acta\nBBA-Proteins Proteomics"},{"issue":"3","key":"2026081311084993000_cit45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1042\/BJ20141127","article-title":"Design, Validation and Efficacy of\nBisubstrate Inhibitors\nSpecifically Affecting Ecto-CK2 Kinase Activity","volume":"471","author":"Cozza","year":"2015","journal-title":"Biochem. J."},{"issue":"14","key":"2026081311084993000_cit46","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1016\/j.bmc.2012.05.038","article-title":"Modified Tetrahalogenated\nBenzimidazoles with CK2 Inhibitory Activity Are Active against Human\nProstate Cancer Cells LNCaP in Vitro","volume":"20","author":"Schneider","year":"2012","journal-title":"Bioorg.\nMed. Chem."},{"issue":"12","key":"2026081311084993000_cit47","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.bioconjchem.5b00383","article-title":"Acetoxymethyl Ester of Tetrabromobenzimidazole\u2013Peptoid Conjugate\nfor Inhibition of Protein Kinase CK2 in Living Cells","volume":"26","author":"Viht","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"2026081311084993000_cit48","doi-asserted-by":"publisher","first-page":"103608","DOI":"10.1016\/j.bioorg.2020.103608","article-title":"Unexpected\nCK2\u03b2-Antagonistic Functionality of Bisubstrate Inhibitors Targeting\nProtein Kinase CK2","volume":"96","author":"Pietsch","year":"2020","journal-title":"Bioorganic Chem."},{"issue":"4","key":"2026081311084993000_cit49","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1021\/jm3012068","article-title":"Principles\nand Applications of Halogen Bonding in Medicinal Chemistry and Chemical\nBiology","volume":"56","author":"Wilcken","year":"2013","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026081311084993000_cit50","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.bmc.2017.02.055","article-title":"Oligo-Aspartic Acid\nConjugates with Benzo[c][2,6]Naphthyridine-8-Carboxylic\nAcid Scaffold as Picomolar Inhibitors of CK2","volume":"25","author":"Vahter","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"2026081311084993000_cit51","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an Orally\nBioavailable Selective Inhibitor\nof Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling\nand Exhibits Antitumor Efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"2026081311084993000_cit52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6125068","article-title":"Structural\nBasis for the Selective Inhibition of Cdc2-Like\nKinases by CX-4945","volume":"2019","author":"Lee","year":"2019","journal-title":"BioMed. Res. Int."},{"issue":"39","key":"2026081311084993000_cit53","doi-asserted-by":"publisher","first-page":"8478","DOI":"10.1021\/bi2008382","article-title":"Unprecedented Selectivity and Structural\nDeterminants of a New Class of Protein Kinase CK2 Inhibitors in Clinical\nTrials for the Treatment of Cancer","volume":"50","author":"Battistutta","year":"2011","journal-title":"Biochemistry"},{"issue":"6","key":"2026081311084993000_cit54","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1107\/S0909049513020785","article-title":"Crystal Structure\nof Human CK2\u03b1\nat 1.06 \u00c5 Resolution","volume":"20","author":"Kinoshita","year":"2013","journal-title":"J. Synchrotron Radiat."},{"issue":"7","key":"2026081311084993000_cit55","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1021\/acschembio.5b00235","article-title":"A Note of\nCaution on the Role of\nHalogen Bonds for Protein Kinase\/Inhibitor Recognition Suggested by\nHigh- And Low-Salt CK2\u03b1 Complex Structures","volume":"10","author":"Guerra","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"2026081311084993000_cit56","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1039\/C7SC05122K","article-title":"Second-Generation CK2\u03b1 Inhibitors\nTargeting the\n\u03b1D Pocket","volume":"9","author":"Iegre","year":"2018","journal-title":"Chem. Sci."},{"issue":"11","key":"2026081311084993000_cit57","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1039\/D2MD00161F","article-title":"A Fragment-Based\nApproach Leading to the Discovery of Inhibitors of CK2\u03b1 with\na Novel Mechanism of Action","volume":"13","author":"Brear","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"1","key":"2026081311084993000_cit58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/molecules25010237","article-title":"Identification\nand Biological Evaluation\nof CK2 Allosteric Fragments through Structure-Based Virtual Screening","volume":"25","author":"Li","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"2026081311084993000_cit59","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1093\/bioinformatics\/btw036","article-title":"Alloscore:\nA Method\nfor Predicting Allosteric Ligand\u2013Protein Interactions","volume":"32","author":"Li","year":"2016","journal-title":"Bioinformatics"},{"key":"2026081311084993000_cit60","unstructured":"Fragments\u2500ChemBridge. https:\/\/chembridge.com\/screening-compounds\/fragments\/(accessed Sep 09, 2025)."},{"issue":"2","key":"2026081311084993000_cit61","doi-asserted-by":"publisher","first-page":"108903","DOI":"10.1016\/j.isci.2024.108903","article-title":"Cancer Selective Cell\nDeath Induction by a Bivalent CK2 Inhibitor Targeting the ATP Site\nand the Allosteric \u03b1D Pocket","volume":"27","author":"Bancet","year":"2024","journal-title":"iScience"},{"issue":"4","key":"2026081311084993000_cit62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.chembiol.2020.12.013","article-title":"Development of a Potent and Selective\nChemical Probe for the Pleiotropic Kinase CK2","volume":"28","author":"Wells","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"2026081311084993000_cit63","doi-asserted-by":"publisher","first-page":"12819","DOI":"10.1021\/acs.jmedchem.5c00695","article-title":"Discovery\nof KDX1381, a Bivalent CK2\u03b1 Inhibitor for the Treatment of Solid\nTumors as a Single Agent or in Combination","volume":"68","author":"Marlhoux","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026081311084993000_cit64","doi-asserted-by":"publisher","first-page":"117826","DOI":"10.1016\/j.ejmech.2025.117826","article-title":"Picomolar Bivalent\nInhibitors of Protein Kinase CK2 Active against \u03b2-Coronavirus\nReplication","volume":"296","author":"Grenier","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"2026081311084993000_cit65","unstructured":"Hyvonen, M. J.; Brear, P.; Spring, D. R.; Glossop, P.\n          Benzo[c][2,6]Naphthyridine\nDerivatives, Compositions and Therapeutic Uses Thereof; WO\n2022185041 A1, September 9, 2022."},{"key":"2026081311084993000_cit66","unstructured":"Hyvonen, M. J.; Brear, P.; Spring, D. R.; Glossop, P.\n          Novel Compounds,\nCompositions and Therapeutic Uses Thereof; WO 2024052690\nA1, March 14, 2024."},{"key":"2026081311084993000_cit67","unstructured":"Hyvonen, M. J.; Brear, P.; Spring, D. R.; Glossop, P.\n          Novel Compounds\nas Ck2 Inhibitors; WO 2024052692 A1, March\n14, 2024."},{"key":"2026081311084993000_cit68","unstructured":"Glossop, P.\n          \n          Prodrugs; WO\n2024052693 A1, March 14, 2024."},{"key":"2026081311084993000_cit69","unstructured":"Glossop, P.; Hyvonen, M. J.; Brear, P.; Spring, D. R.\n          Novel Compounds,\nCompositions and Therapeutic Uses Thereof; WO 2024052701\nA1, March 14, 2024."},{"key":"2026081311084993000_cit70","unstructured":"Glossop, P.; Hyvonen, M. J.; Brear, P.; Spring, D. R.\n          Novel Compounds\nas Ck2 Inhibitors; WO 2024052702 A1, March\n14, 2024."},{"issue":"20","key":"2026081311084993000_cit71","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1021\/acs.jmedchem.5c01807","article-title":"Exploiting the Cryptic \u03b1D Pocket of Casein Kinase\n2\u03b1 (CK2\u03b1) to Deliver Highly Potent and Selective Type\n1 Inhibitors","volume":"68","author":"Glossop","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026081311084993000_cit72","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-2125.2002.01595.x","article-title":"Dose-Dependent Increase of Saquinavir\nBioavailability by the Pharmaceutic Aid Cremophor EL","volume":"53","author":"Martin-Facklam","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026081311084993000_cit73","unstructured":"Apollo Therapeutics Ltd.\n          . A Phase 1\/2\nStudy to Assess the Safety\nand Antitumor Activity of APL-5125 in Adults With Selected Advanced\nSolid Tumors; Clinical trial registration NCT06399757; clinicaltrials.gov, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06399757 (accessed Nov 03, 2025)."},{"issue":"5","key":"2026081311084993000_cit74","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1158\/1535-7163.MCT-08-1056","article-title":"Anticancer\nPeptide\nCIGB-300 Binds to Nucleophosmin\/B23, Impairs Its CK2-Mediated Phosphorylation,\nand Leads to Apoptosis through Its Nucleolar Disassembly Activity","volume":"8","author":"Perera","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"2026081311084993000_cit75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2016.05.026","article-title":"CIGB-300, an Anti-CK2 Peptide, Inhibits Angiogenesis,\nTumor Cell Invasion and Metastasis in Lung Cancer Models","volume":"107","author":"Benavent Acero","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"2026081311084993000_cit76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.seminoncol.2018.04.006","article-title":"CIGB-300: A Peptide-Based\nDrug That Impairs the Protein Kinase CK2-Mediated Phosphorylation","volume":"45","author":"Perea","year":"2018","journal-title":"Semin. Oncol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c00643","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17584\/66305083\/acs.jmedchem.6c00643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17584\/66305083\/acs.jmedchem.6c00643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:10:54Z","timestamp":1786633854000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/15\/17584\/5235361\/Selective-Inhibition-of-CK2-Emerging-Strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":76,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00643","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}